Skip to main content
. Author manuscript; available in PMC: 2010 Oct 11.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):113–120. doi: 10.1158/1055-9965.EPI-08-0591

Table 2.

Final multivariate logistic regression model (polytomous) of HPV cofactors among women enrolled in SUCCEED restricted to women infected with (i) any HPV type, (ii) oncogenic-HPV types, (iii) HPV16 only, (iv) HPV16 or -18, (v) oncogenic HPV types excluding HPV16 and HPV18. Final models include all variables listed and age (quintiles) for comparisons of: (a) CIN3 compared to <CIN2, and (b) CIN2 compared to <CIN2.

Characteristic CIN3 v <CIN2 CIN2 v <CIN2
All HPV
OR (95% CI)		 Oncogenic HPV
OR (95% CI)		 HPV16
OR (95% CI)		 HPV16 or 18
OR (95% CI)		 Non-HPV16, 18
OR (95% CI)		 All HPV
OR (95% CI)		 Oncogenic HPV
OR (95% CI)		 HPV16
OR (95% CI)		 HPV16 or 18
OR (95% CI)		 Non-HPV16, 18
OR (95% CI)
Race
  White 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
  Black 0.6 (0.3–1.0) 0.7 (0.4–1.1) 0.9 (0.4–2.1) 1.0 (0.4–2.1) 0.9 (0.4–2.1) 0.8 (0.5–1.2) 0.9 (0.6–1.3) 1.5 (0.7–3.1) 1.6 (0.8–3.1) 0.7 (0.4–1.3)
  Other 0.9 (0.5–1.5) 0.9 (0.6–1.6) 1.1 (0.5–2.4) 1.1 (0.5–2.2) 0.7 (0.2–2.3) 1.1 (0.7–1.8) 1.2 (0.7–1.8) 1.2 (0.5–2.7) 1.0 (0.5–2.2) 1.4 (0.7–2.6)
Income ($)
  <10,000 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
  10,001–40,000 1.2 (0.9–1.7) 1.3 (0.9–1.8) 1.6 (1.0–2.6) 1.5 (1.0–2.4) 1.0 (0.6–2.0) 1.2 (0.9–1.6) 1.2 (0.9–1.7) 1.9 (1.1–3.0) 1.6 (1.0–2.4) 0.9 (0.6–1.4)
  40,000+ 1.9 (1.0–3.6) 2.0 (1.0–3.8) 2.4 (0.9–6.5) 2.0 (0.8–4.9) 3.9 (1.2–12.6) 1.3 (0.7–2.4) 1.3 (0.7–2.5) 2.6 (1.0–7.2) 2.3 (0.9–5.7) 0.8 (0.3–2.1)
Lifetime number of sexual partners
  1 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
  2–3 1.1 (0.6–2.3) 1.1 (0.5–2.3) 2.9 (0.9–9.2) 2.2 (0.7–6.3) 0.3 (0.1–1.0) 1.6 (0.9–2.9) 1.5 (0.8–2.9) 2.2 (0.7–6.7) 1.9 (0.7–5.3) 1.2 (0.5–2.8)
  4–10 1.4 (0.7–2.7) 1.3 (0.7–2.6) 2.6 (0.9–7.8) 1.9 (0.7–5.4) 0.6 (0.2–1.7) 1.5 (0.8–2.7) 1.4 (0.8–2.7) 1.9 (0.7–5.6) 1.6 (0.6–4.3) 1.1 (0.5–2.7)
  11+ 1.4 (0.7–2.8) 1.4 (0.6–2.9) 2.8 (0.8–8.9) 1.7 (0.6–5.1) 0.7 (0.2–2.2) 1.2 (0.6–2.3) 1.1 (0.5–2.2) 1.2 (0.4–3.9) 0.9 (0.3–2.6) 1.2 (0.5–3.1)
Number of pregnancies
  0 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
  1–3 1.6 (1.1–2.3) 1.5 (1.0–2.3) 1.2 (0.7–2.1) 1.2 (0.7–1.9) 3.2 (1.2–8.4) 1.0 (0.8–1.4) 1.0 (0.7–1.3) 0.7 (0.4–1.3) 0.8 (0.5–1.3) 1.1 (0.7–1.9)
  4+ 2.1 (1.3–3.6) 2.0 (1.2–3.3) 1.7 (0.8–3.6) 1.7 (0.9–3.4) 3.3 (1.1–10.2) 1.1 (0.7–1.8) 0.9 (0.5–1.5) 0.7 (0.3–1.6) 0.7 (0.3–1.5) 1.3 (0.6–2.7)
Smoking
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
  Current 2.5 (1.8–3.6) 2.5 (1.8–3.6) 2.7 (1.6–4.6) 2.9 (1.8–4.7) 2.0 (1.0–3.8) 1.3 (0.9–1.7) 1.3 (0.9–1.8) 1.9 (1.1–3.2) 1.7 (1.1–2.8) 1.0 (0.6–1.5)
  Former 1.4 (0.9–2.3) 1.5 (0.9–2.4) 1.6 (0.8–3.2) 1.8 (0.9–3.4) 1.4 (0.6–3.4) 0.8 (0.5–1.2) 0.8 (0.5–1.3) 0.8 (0.3–1.8) 0.9 (0.4–1.9) 0.8 (0.4–1.4)
Oral contraceptive use
  Never 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
  Ever 1.1 (0.7–1.6) 1.1 (0.7–1.7) 0.9 (0.5–1.7) 1.0 (0.6–1.8) 2.0 (0.7–6.1) 1.0 (0.7–1.5) 1.1 (0.7–1.6) 1.4 (0.7–2.8) 1.7 (0.9–3.2) 0.7 (0.4–1.3)
BMI
  20–<25 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
  25–<30 1.4 (0.9–2.0) 1.4 (0.9–2.1) 1.5 (0.9–2.7) 1.5 (0.9–2.4) 1.7 (0.8–3.5) 0.9 (0.6–1.2) 0.8 (0.6–1.2) 1.0 (0.6–1.8) 1.1 (0.7–1.8) 0.6 (0.4–1.1)
  30+ 1.5 (1.0–2.2) 1.6 (1.1–2.3) 1.6 (0.9–2.7) 1.5 (0.9–2.6) 2.0 (1.0–4.2) 0.8 (0.6–1.1) 0.8 (0.6–1.2) 0.7 (0.4–1.4) 0.8 (0.5–1.4) 0.7 (0.4–1.2)
  <20 2.0 (1.3–3.1) 2.0 (1.3–3.2) 2.3 (1.2–4.3) 2.5 (1.4–4.6) 1.3 (0.5–3.7) 1.1 (0.7–1.7) 1.2 (0.8–1.8) 1.2 (0.6–2.3) 1.4 (0.8–2.7) 0.9 (0.5–1.8)